The strong revenue growth, particularly in Decipher (27% growth) and Afirma tests, combined with margin expansion and robust cash flow, suggests improving fundamentals. The reiterated 2026 guidance provides visibility, but investors should monitor the impact of new product launches (Prosigna LDT, TrueMRD) on future growth.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $38.75entry
- T+1 · 9mo ago −5.57%α −5.09% · $36.59
- T+5 · 9mo ago −10.50%α −9.34% · $34.68
- T+20 · 8mo ago −15.35%α −8.94% · $32.80
- T+60 · 6mo ago +16.21%α +8.03% · $45.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Veracyte reported strong fourth quarter and full year 2025 financial results, with Q4 total revenue up 19% year-over-year to $140.6 million and full year revenue up 16% to $517.1 million. The company delivered GAAP net income of $66.4 million and generated $136.3 million in operating cash flow. Management reiterated 2026 revenue guidance of 10-13% growth.
Key Financial Metrics
Key Facts
- Q4 2025 total revenue: $140.6 million (19% YoY growth)
- Full year 2025 total revenue: $517.1 million (16% YoY growth)
- Q4 2025 GAAP net income: $41.1 million (29.3% of revenue)
- Full year 2025 GAAP net income: $66.4 million (12.8% of revenue)
- Generated $136.3 million in cash from operations for full year 2025
- Reiterated 2026 revenue guidance of $570-$582 million (10-13% growth)
Financial Impact
Revenue growth of 16-19% and net income growth of 175% YoY with strong cash flow generation of $136.3 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Decipher | $310.7M | +27.0% |
| Afirma | $172.9M | +9.0% |
Risk Factors
- Biopharmaceutical and other revenue declined due to restructuring of Veracyte SAS
- Future guidance excludes contribution from new tests, creating uncertainty about full-year performance
- Adjusted EBITDA margin expected to decrease to ~25% in 2026 from 27.6% in 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001384101-26-000008 |
| Document: vcyt-20260225.htm | 0001384101-26-000008 |
| Document: 0001384101-26-000008-index-headers.html | 0001384101-26-000008 |
| Document: 0001384101-26-000008-index.html | 0001384101-26-000008 |
| Document: 0001384101-26-000008.txt | 0001384101-26-000008 |
Track record
22 reports on VCYT
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.37% at T+20 after the Jun 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $24.63 Now $24.01 −2.52% settles Dec 11
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $50.01 Now $24.01 −51.99% settles Nov 30
- Oct 28, 202619d ago Insider Cluster Neutral 2/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 28, 202619d ago Insider Cluster Neutral 3/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
- Sep 22, 20267w ago Insider Cluster Neutral 2/10 Entry $43.82 to $46.22 Now $24.01 −45.21% ▲ +5.48% +4.79% vs SPY
- Sep 14, 20269w ago Press Release Bullish 6/10 Entry $40.14 to $43.11 Now $24.01 −40.18% ▲ +7.40% +4.68% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers